Jirong Pharm

Jirong Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing innovative small molecule drugs for oncology and autoimmune disorders. The company leverages its proprietary drug discovery platform to create highly selective inhibitors against validated but challenging targets. Its lead program, JR-442, is a next-generation URAT1 inhibitor currently undergoing Phase 2 clinical evaluation for hyperuricemia and gout. Jirong's pipeline also includes JR-101, targeting EGFR exon 20 insertion mutations in lung cancer, and JR-2022, a selective TYK2 inhibitor for various inflammatory diseases. Supported by prominent venture capital firms, the company aims to provide more effective and safer treatment options for patients globally.